Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-β- cyclodextrin

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 3, 2012, Pages 596-603

  Glisoni, Romina J ^a,b   Cuestas, María L ^a,b   Mathet, Verónica L ^a,b   Oubiña, José R ^a,b   Moglioni, Albertina G ^a,b   Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

1 Indanone thiosemicarbazones; Antiviral activity; HCV replicon systems; Hepatitis C virus (HCV); Hydroxypropyl cyclodextrin; Inclusion complexes

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 5,6 DIMETHOXY 1 INDANONE N4 ALLYL THIOSEMICARBAZONE; 5,6 DIMETHOXY 1 INDANONE THIOSEMICARBAZONE; CAVASO; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; HEPACIVIRUS; HUMANS; RNA, VIRAL; THIOSEMICARBAZONES; VIRUS REPLICATION;

EID: 84865409105     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.07.018     Document Type: Article

References (37)

1. U.A. Ashfaq, M.Z. Yousaf, M. Aslam, R. Ejaz, S. Jahan, and O. Ullah SiRNAs: potential therapeutic agents against Hepatitis C Virus Virol. J. 8 2011 276
2. M. Bencini, E. Ranucci, P. Ferruti, F. Trotta, M. Donalisio, M. Cornaglia, D. Lembo, and R. Cavalli Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a β-cyclodextrin/ poly(amidoamine) copolymer J. Control. Rel. 126 2008 17 25
3. K.J. Blight, J.A. McKeating, and C.M. Rice Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication J. Virol. 76 2002 13001 13014
4. M. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Del. Rev. 59 2007 645 666
5. M.E. Caputto, L.E. Fabian, D. Benítez, A. Merlino, N. Ríos, H. Cerecetto, G.Y. Moltrasio, A.G. Moglioni, M. González, and L.M. Finkielsztein Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents Bioorg. Med. Chem. 19 2011 6818 6826
6. E.F. Castro, L.E. Fabian, M.E. Caputto, D. Gagey, L.M. Finkielsztein, G.Y. Moltrasio, A.G. Moglioni, R.H. Campos, and L.V. Cavallaro Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone J. Virol. 85 2011 5436 5445
7. M.L. Cuestas, A. Sosnik, and V.L. Mathet Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines Mol. Pharm. 8 2011 1152 1164
8. G. Domagk, R. Behnisch, F. Mietzsch, and H. Schimidt On a new class of compounds effective in vitro against tubercle bacilli Naturwissenschaften 33 1946 315
9. X. Du, C. Guo, E. Hansell, P.S. Doyle, C.R. Caffrey, T.P. Holler, J.H. McKerrow, and F.E. Cohen Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain J. Med. Chem. 45 2002 2695 2707
10. L.M. Finkielsztein, E.F. Castro, L.E. Fabian, G.Y. Moltrasio, R.H. Campos, L.V. Cavallaro, and A.G. Moglioni New-1-indanone thiosemicarbazone derivatives active against BVDV Eur. J. Med. Chem. 43 2008 1767 1773
11. R.J. Glisoni, D.A. Chiappetta, L.M. Finkielsztein, A.G. Moglioni, and A. Sosnik Self-aggregation behaviour of novel thiosemicarbazone drug candidates with potential antiviral activity New J. Chem. 34 2010 2047 2058
12. R.J. Glisoni, D.A. Chiappetta, A.G. Moglioni, and A. Sosnik Novel 1-Indanone thiosemicarbazone antiviral candidates: aqueous solubilization and physical stabilization by means of cyclodextrins Pharm. Res. 29 2012 739 755
13. N. Gómez, D. Santos, R. Vázquez, L. Suescun, A. Mombrú, M. Vermeulen, L. Finkielsztein, C. Shayo, A. Moglioni, D. Gambino, and C. Davio Synthesis, Structural characterization, and pro-apoptotic activity of 1-indanone thiosemicarbazone platinum(II) and palladium(II) complexes: potential as antileukemic agents ChemMedChem 6 2011 1485 1494
14. S. Gould, and R. Scott 2-Hydroxypropyl-β-cyclodextrin (HPβ-CD): a toxicology review Food Chem. Toxicol. 43 2005 1451 1459
15. N. Grancher, V. Venard, F. Kedzierewicz, W. Ammerlaan, C. Finance, A. Muller, and C.P. Le Faou Improved antiviral activity in vitro of ribavirin against measles virus after complexation with cyclodextrins Antiviral Res. 62 2004 135 137
16. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J. Hepatol. 55 2011 192 206
17. A.K. Halve, B. Bhashkar, V. Sharma, R. Bhadauria, A. Kankoriya, A. Soni, and K. Tiwari Synthesis and in vitro antimicrobial studies of some new 3-[phenyldiazenyl] benzaldehyde N-phenyl thiosemicarbazones J. Enzym. Inhib. Med. Chem. 23 2008 77 81
18. U.C. Hipler, U. Schonfelder, C. Hipler, and P. Elsner Influence of cyclodextrins on the proliferation of HaCaT keratinocytes in vitro J. Biom. Mat. Res. Part A 83 2007 70 79
19. C.H. Hung, C.M. Lee, and S.N. Lu Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications Expert Rev. Anti. Infect. Ther. 9 2011 525 533
20. B. Hunyadi New therapeutic options in chronic hepatitis C virus infection Orv. Hetil. 152 2011 887 897
21. Z. Iakovidou, A. Papageorgiou, M.A. Demertzis, E. Mioglou, D. Mourelatos, A. Kotsis, Yadav P. Nath, and D. Kovala-Demertzi Platinum (II) and Palladium (II) complexes with 2-acetylpyridine thiosemicarbazone: cytogenetic and antineoplastic effects Anti-Cancer Drugs 12 2001 65 70
22. M. Lakatos, K. Hagymási, and G. Lengyel Fatty liver and hepatitis C virus infection Orv. Hetil. 152 2011 1513 1519
23. M. Masarone, and M. Persico Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev. Anti. Infect. Ther. 9 2011 535 543
24. L. Matilainen, T. Toropainen, H. Vihola, J. Hirvonen, T. Järvinen, P. Jarho, and K. Järvinen In vitro toxicity and permeation of cyclodextrins in Calu-3 cells J. Control. Rel. 126 2008 10 16
25. M. Messner, S.V. Kurlov, P. Jansook, and T. Loftsson Self-assembled cyclodextrin aggregates and nanoparticles Int. J. Pharm. 387 2009 199 208
26. A.P. Mukne, and M.S. Nagarsenker Triamterene-β-cyclodextrin system: preparation, characterization and in vivo evaluation AAPS PharmSciTech 5 2004 1 9
27. C. Nicolazzi, V. Venare, A. La Faou, and C. Finance In vitro antiviral efficacy of the ganciclovir complexed with beta-cyclodextrin on human cytomegalo virus clinical strains Antiviral Res. 54 2002 121 127
28. C. Okuse, J.A. Rinaudo, K. Fardar, F. Wells, and B.E. Korba Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy Antiviral Res. 65 2005 23 34
29. M. Pawlowska Attempts to treat chronic hepatitis C with HCV protease inhibitor Przegl. Epidemiol. 65 2011 35 38
30. G. Pelosi, F. Bisceglie, F. Bignami, P. Ronzi, P. Schiavone, M.C. Re, C. Casoli, and E. Pilotti Antiretroviral activity of thiosemicarbazone metal complexes J. Med. Chem. 53 2010 8765 8769
31. F. Poordad, and V. Khungar Emerging therapeutic options in hepatitis C virus infection Am. J. Manag. Care. 17 2011 S123 S130
32. H.R. Rosen Chronic hepatitis C infection N. Engl. J. Med. 364 2011 2429 2438
33. M.L. Shiffman Interferon-free regimens: the near future, the likely and the not so likely Clin. Liver Dis. 15 2011 665 675
34. V. Soriano, E. Vispo, E. Poyeda, P. Labarga, L. Martin-Carbonero, J.V. Fernandez-Montero, and P. Barreiro Directly acting antivirals against hepatitis C virus J. Antimicrob. Chemother. 66 2011 1673 1686
35. D. Sriram, P. Yogeeswari, P. Dhakla, P. Senthilkumar, and D. Banerjee N-Hydroxythiosemicarbazones: synthesis and in vitro antitubercular activity Bioorg. Med. Chem. Lett. 17 2007 1888 1891
36. C. Udata, J. Patel, D. Pal, E. Hejchman, M. Cushman, and A.K. Mitra Enhanced transport of a novel anti-HIV agent-cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers Int. J. Pharm. 250 2003 157 168
37. J. Vermehren, and C. Sarrazin New hepatitis C therapies in clinical development Eur. J. Med. Res. 16 2011 303 314